alnuctamab,dexamethasone
allogene therapeutics,bms
['mmsm', 'equate', '#162', 'alnuctamab', '2019', 'dexamethasone', 'emergent ', 'effector ']
you can call me al(nuctamab) - it s back as sq. shows long term results w/ iv alnuctamab had a median dor of 36 months(!) but crs rates high. sq alnuctamab with orr 65%. lower crs rates. 90% w/ongoing responses. the dor is really impressive! #ash22 #mmsm 
Asst Professor at University of Chicago, specializing in (vanquishing) plasma cell disorders. I tweet about: Myeloma & MRD. https://t.co/mPeWg1QRrW